| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1374193 | Bioorganic & Medicinal Chemistry Letters | 2009 | 4 Pages |
Abstract
The STAT3 oncogene is a promising molecular target for the design of a new class of anticancer drugs. In this letter, we describe the design, synthesis, and evaluation of peptidomimetics containing Freidinger lactams as novel STAT3 inhibitors. Compound 3 binds to STAT3 with a Ki value of 190 nM and is a promising lead compound for further design and optimization.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Cindy Gomez, Longchuan Bai, Jian Zhang, Zaneta Nikolovska-Coleska, Jianyong Chen, Han Yi, Shaomeng Wang,